Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab plus 26-week glucocorticoid taper vs placebo plus 52-week taper in giant cell arteritis
2020-004809-31Phase 3Active
- Sponsor
- Novartis
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) comparing Secukinumab + 26-week glucocorticoid taper with Placebo + 52-week glucocorticoid taper (2 arms). Primary endpoint: Sustained remission. Started Jun 2021; status: active.
02
Drugs
secukinumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2020-004809-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004809-31.